In vivo studies show that a single oral administration of RG-7112 can activate p53 pathway, induce tumor cell apoptosis, reduce tumor growth and improve survival in GBM models.370,371 The earliest phase I clinical trial of RG-7112 (NCT00559533) began in November 2017. Here, TP53 is linked to neoplasm.